Pre-operative high-dose-rate brachytherapy in early-stage cervical cancer: long-term single-center results

Sylwia Kellas-Ślęczka; Piotr Wojcieszek; Marta Szlag; Magdalena Stankiewicz; Agnieszka Cholewka; Maciej Ślęczka; Agnieszka Badora-Rybicka; Piotr Lelek; Agnieszka Pruefer; Tomasz Krzysztofiak; Zofia Kołosza; Marek Fijałkowski

doi:10.5114/jcb.2022.112697

Pre-operative high-dose-rate brachytherapy in early-stage cervical cancer: long-term single-center results

J Contemp Brachytherapy. 2022 Feb;14(1):43-51. doi: 10.5114/jcb.2022.112697. Epub 2022 Jan 19.

Affiliations

¹ Brachytherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.
² Radiotherapy Planning Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.
³ Institute of Mathematics, University of Silesia in Katowice, Katowice, Poland.
⁴ Breast Cancer Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.
⁵ Department of Biostatistics and Bioinformatics, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.

Abstract

Purpose: The aim of the study was to report the outcomes of pre-operative high-dose-rate brachytherapy (pHDR-BT), followed by hysterectomy in patients with early cervical cancer.

Material and methods: From January, 1998 to December, 2003, 113 women with IB1, IB2, and IIA1 cervical cancer (according to International Federation of Gynecology and Obstetrics [FIGO] 2018) were treated with pHDR-BT, and 6 to 8 weeks later followed by radical hysterectomy. Patients found to have positive lymph nodes, residual cervical cancer, involved parametria, or lymphovascular space invasion (LVSI) received post-operative adjuvant therapy.

Results: Post-operatively, 81.4% of patients had a complete response to pHDR-BT in the cervix, and 18.6% had residual cervical cancer. Failures occurred in 11/113 (9.7%) patients (all were stage IIA1), with pelvic recurrences in 5/113 (4.4%) and distant metastasis (DM) in 6/113 (5.3%). The 5- and 10-year disease-free survival (DFS) rates were 100% for IB1 and IB2, and 86.4% and 81.3% for IIA1, respectively. Lymph node involvement and/or residual cervical cancer correlated with worse DFS. Two vesicovaginal fistulas were observed (one in a patient treated only with pHDR-BT and one in a woman, who underwent adjuvant external-beam radiotherapy [EBRT]). Two rectovaginal fistulas and one case of proctitis were observed in patients treated with adjuvant EBRT.

Conclusions: pHDR-BT in early cervical cancer is well-tolerated and effective in sterilizing tumor cells in the cervix. The growing number of publications in this area may help define an optimal therapeutic scheme, but randomized trials are required to determine the best candidates for this treatment modality.In our opinion, cervical cancer patients with FIGO stage IIA1 are not good candidates for pHDR-BT, and could be given this treatment only after rigorous selection, including assessment with state-of-the-art imaging, due to higher probability of treatment failure.

Keywords: HDR; brachytherapy; cervical cancer; pre-operative.